National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Anthrax is not the name you expected.

Disorder Subdivisions

  • None

General Discussion

Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. It is usually a disease of wild and domestic animals, including cattle, sheep, and goats. However, human infection, while rare, does occur. Human infection usually results from contact with infected animals or their products. However, anthrax has become of interest because of the possibility that a nation or terrorist group might attempt to use it as a weapon of warfare or terrorism. There are three types of anthrax: cutaneous (through the skin), gastrointestinal, and inhalational.


Symptoms usually appear within seven days of exposure, although in some cases the incubation period has been significantly longer than this.

Cutaneous anthrax begins with a raised area on the skin that itches (pruritic papule). Usually, this occurs on exposed areas, most often on the arms and hands followed by the face and neck. It resembles an insect bite. This area becomes larger and, within one or two days, develops into an ulcer, surrounded by small blisters containing fluid. A characteristic black, crusty spot develops on the affected skin area later and, after a few weeks, begins to loosen and ultimately falls off, leaving a scar. The course of these events is so characteristic that the diagnosis is not often missed by physicians familiar with the disease, even though it is rare.

Gastrointestinal anthrax can present as either intestinal or throat and pharynx (oropharyngeal) disease. The symptoms for intestinal infection include fever, nausea, abdominal pain, vomiting, and anorexia. As the disease progresses, there may also be vomiting of blood, bloody diarrhea, toxemia, shock and a bluish tinge to the skin and mucous membranes (cyanosis). Symptoms for oropharyngeal illness may include fever, sore throat, difficulty in swallowing (dysphagia), collection of fluid (edema) in the tissues of the throat, and swelling of the lymph nodes.

Inhalational anthrax typically begins with one to three days of fatigue, low-grade fever, and dry cough. These symptoms, typical of a mild upper respiratory tract infection, may be accompanied by an ache of feeling of heaviness in the chest and the area just below the chest. Following this relatively mild onset, there will be a period of more intense illness characterized by high fever, elevation of the pulse and respiratory rate, heavy perspiration (profuse diaphoresis), and difficult or labored breathing (dyspnea).


Anthrax is primarily a disease of animals, specifically herbivores such as cattle, goats, and sheep. They contract the disease after coming into contact with B. anthracis spores, which are present in the soil around the world. The rare cases when humans are infected typically occur when people come into contact through their occupations with infected animals or when people eat undercooked meat or other products from infected animals. Its occurrence is most likely in developing countries, although animal products imported from those countries may pose a risk.

Human infection sometimes results from contact in an industrial setting. In the United States, there have been occasional episodes in industrial settings resulting from, for instance, processing contaminated animal fibers such as goat hair.

Infection may also occur among those who work in agricultural jobs. These infections typically occur among people who have had direct contact with animals sick with anthrax or those who have died with the disease.

Cutaneous anthrax occurs after spores come into contact with skin that is broken as a result of a wound or lesion. Gastrointestinal anthrax occurs as a result of eating poorly cooked or raw meat from animals that are infected with the disease. Inhalational anthrax occurs as a result of breathing in (inhaling) the spores.

There have been no confirmed cases of person-to-person transmission of cutaneous, gastrointestinal, or inhalational anthrax. For this reason, it is believed unnecessary to immunize or treat the family members, friends, or co-workers of those who become ill with anthrax unless it is possible that they have been exposed to the same original source of the infection.

Affected Populations

Anthrax is most common in developing countries. It can be found globally, although the regions of the world with the greatest incidence of agricultural anthrax are South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East.

The largest reported agricultural outbreak occurred in Zimbabwe, with more than 10,000 cases reported between 1979 and 1985.

In 1979, 79 cases of inhalational anthrax were reported in the area of Sverdlovsk, Russia. Sixty-eight of those cases ultimately were fatal. It is believed that this outbreak was caused by the accidental release of aerosolized anthrax spores from a military laboratory.


Cutaneous anthrax may be diagnosed by the characteristic signs, such as the raised area on the skin and detection of the presence of the anthrax bacilli in the area of the lesion. A history of exposure to livestock or other possible animal sources also is important. Gastrointestinal anthrax is more difficult to diagnose. In the first, mild phase of inhalational anthrax, symptoms resemble a common cold or upper respiratory infection. With the sudden onset of the more severe symptoms of the second phase, radiographic examination of the chest may show characteristic changes.

Standard Therapies


Antibiotics, such as penicillin, are used to treat all forms of anthrax. However, to be effective, treatment must be started as soon as possible after exposure. Once symptoms begin, there is a significant decline in the likelihood that treatment will be successful.

An antibiotic known as ciprofloxacin (Cipro) was approved in August 2000 by the U.S. Food and Drug Administration for treating people who have been exposed to inhalational anthrax. However, Cipro, too, needs to be taken soon after exposure, and before symptoms begin, to be effective. Taking this or other antibiotics before exposure, as a preventive measure, is not recommended and may cause harm. Before being approved for this purpose, Cipro had been used for several years to treat a variety of infections, including cutaneous anthrax.

Once symptoms have begun, antibiotic therapy is rarely successful against the gastrointestinal or inhalational forms of the disease.

For more information about antibiotic treatments used for anthrax, you may access the following government web sites:

Cipro (Ciprofloxacin): Use by Pregnant and Lactating Women (7/21/2015); <a href="">//</a>

Doxycycline: Questions and Answers for Consumers (7/21/2015); <a href="">//</a>

Doxycycline (Vibramycin, Monodox, Doryx, Doxy, Atridox, Periodox, Vibra_Tabs): Use by Pregnant and Lactating Women (7/21/2015); <a href="">//</a>

Drug Preparedness and Response to Bioterrorism (7/21/2015); <a href="">//</a>

In 2015, Anthrasil, anthrax immune globulin intravenous (human) was approved to treat patients with inhalational anthrax in combination with appropriate antibacterial drugs. The product is manufactured by Cangene Corporation.

Investigational Therapies

Information on current clinical trials is posted on the Internet at All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010


For information about clinical trials sponsored by private sources, contact:

Research is underway on vaccines to prevent anthrax.

Healthy volunteers are being recruited for a phase II study of a recombinant anthrax vaccine, rPA102, being developed by VaxGen, Inc., under a contract with the U.S. government through the National Institute of Allergy and Infectious Diseases (NIAID). The study is being conducted at 12 centers throughout the U.S. by the Center for Vaccine Development in collaboration with SoLUtions, a clinical research organization, both of Saint Louis University School of Medicine. Healthy individuals between the ages of 18 and 55, who have not served in the Armed Forces, active or reserve, since 1990, may be eligible to participate. For information, contact:


Saint Louis University


Salus Center, 2nd Floor

3545 Lafayette Avenue

St. Louis, MO 63104-1314

Telephone: (314) 977-7520

NIAID is also sponsoring a study of the natural history of anthrax, focusing on infected or exposed individuals to learn more about the disease symptoms, prevention, and response to treatment. People who have been exposed to anthrax but have no clinical symptoms, people with confirmed or suspected anthrax, and healthy people who have been vaccinated with AVA (Anthrax Vaccine Adsorbed) may be eligible to participate in this study. For information, contact the NIH Patient Recruitment Office listed above or visit



Berkow R, ed. The Merck Manual-Home Edition. Whitehouse Station, NJ: Merck Research Laboratories; 1997:863.

Beers MH, Berkow R, eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:1157-58.

Lew D, Bacillus Anthracis (Anthrax). In: Mandell GL, et al., eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone Inc; 1995:1885-89.


Bailie L, et al. Bacillus Anthracis, a bug with attitude! Curr Opin Microbiol. 2001;4:78-81.

Friedlander AM. Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr Clin Top Infect Dis. 2000;20:335-49.

Jefferson T, et al. Vaccines for preventing anthrax. Cochrane Database Syst Rev. 2000:CD000975.

Shafazand S, et al. Inhalation anthrax: epidemiology, diagnosis, and management. Chest. 1999; 116:1369-76.


Mourez M, et al. Designing a polyvalent inhibitor of anthrax toxin. Nat Biotechnol. 2001;19:958-61.

Cheun HI, et al. A simple and sensitive detection system for Bacillus anthracis in meat and tissue. J Appl Microbiol. 2001;91:421-26

Price BM, et al. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immunol. 2001;69:4509-15.

[No authors listed.] Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices. J Toxicol Clin Toxicol. 2001;39:85-100.

Kiel JL, et al. Rapid recovery and identification of anthrax bacteria from the environment. Ann N Y Acad Sci. 2000;916:240-52.

Supporting Organizations

Centers for Disease Control and Prevention

1600 Clifton Road NE
Atlanta, GA 30333
Tel: (404)639-3534
Tel: (800)232-4636
Website: //

Genetic and Rare Diseases (GARD) Information Center

PO Box 8126
Gaithersburg, MD 20898-8126
Tel: (301)251-4925
Fax: (301)251-4911
Tel: (888)205-2311
Website: //

NIH/National Institute of Allergy and Infectious Diseases

NIAID Office of Communications and Government Relations
5601 Fishers Lane, MSC 9806
Bethesda, MD 20892-9806
Tel: (301)496-5717
Fax: (301)402-3573
Tel: (866)284-4107
Website: //

World Health Organization (WHO)

Avenue Appia 20
Geneva 27, 1211
Tel: 41227912111
Fax: 41227913111
Website: //

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see